Navigation Links
Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
Date:6/18/2008

SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Frank Karbe, executive vice president and chief financial officer at Exelixis, will present at the Piper Jaffray Europe Conference at 3:40 a.m. PT/6:40 a.m. ET/11:40 a.m. London, UK time on Wednesday, June 25, 2008. Mr. Karbe will discuss updates to the company's development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions ... scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):